Inovio Pharmaceuticals Inc vs Roundhill Russell 2000 0DTE Covered Call Strat ETF — how do they compare? Inovio Pharmaceuticals Inc trades at $1.12 (market cap $112.19M), while Roundhill Russell 2000 0DTE Covered Call Strat ETF trades at $26.13 (market cap $159.33M). The key difference: Roundhill Russell 2000 0DTE Covered Call Strat ETF is the larger of the two by market cap, and Inovio Pharmaceuticals Inc is trading nearer its 52-week high, Roundhill Russell 2000 0DTE Covered Call Strat ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and Roundhill Russell 2000 0DTE Covered Call Strat ETF for 54 Days on average.
| INO | RDTE | |
|---|---|---|
Market Cap | $112.19M | $159.33M |
Volume | 3,201,278 | 248,058 |
Sector | Health | Income / Options Overlay |
52-Week High | $2.65 | $33.66 |
52-Week Low | $0.66 | $25.96 |
Typical Hold Time | 43 Days | 54 Days |
Enterprise Value | $83.51M | — |
Signals from Pluang's Aura AI — not financial advice
Inovio Pharmaceuticals (INO) trades at $1.09, down 5.63% today, reflecting ongoing financial challenges with minimal revenue of $65,340 in 2025 and substantial losses. The company shows consistent negative cash flow from operations but has beaten EPS estimates in recent quarters. Technical indicators are bearish, with moving averages and oscillators signaling selling pressure. Key near-term catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, its lead candidate for recurrent respiratory papillomatosis.
The investment case hinges on FDA approval of INO-3107, with analyst consensus target at $2.75 offering significant upside. However, high burn rate, negative margins, and dependence on financing pose substantial risks. Positive regulatory outcome could drive revaluation, but failure may exacerbate financial strain. Wall Street maintains cautious optimism with 59% buy ratings.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →RDTE is an actively managed ETF that seeks to generate income through a covered call strategy on the Russell 2000 Index. The fund primarily holds a portfolio of short-term U.S. government securities and sells 0-DTE (zero days to expiration) index call options on the Russell 2000. This highly tactical strategy aims to maximize premium capture by exploiting the high time decay of options that are expiring on the same day, which provides enhanced income but also exposes the fund to significant volatility and risks associated with daily options settlement.
Read more on RDTE →